Search

Your search keyword '"Corn, Paul G."' showing total 196 results
Start Over Author "Corn, Paul G." Publication Year Range Last 3 years
196 results on '"Corn, Paul G."'

1. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract

Author

Alhalabi, Omar, Wilson, Nathaniel, Xiao, Lianchun, Lin, Yiyun, Khandelwal, Jaanki, Moussa, Mohammad Jad, Msaouel, Pavlos, Navai, Neema, Gao, Jianjun, Kamat, Ashish M., Pilie, Patrick, Shah, Amishi Y., Goswami, Sangeeta, Matin, Surena, Kovitz, Craig, Holla, Vijaykumar, Guo, Charles, Czerniak, Bogdan, Logothetis, Christopher, Corn, Paul G., Dinney, Colin P.N., Campbell, Matthew T., Hansel, Donna E., Tannir, Nizar M., and Siefker-Radtke, Arlene O.

Published
2023
Full Text
View/download PDF

2. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

3. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

4. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

7. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.

Author

Guoyu Yu, Corn, Paul G., Sze Ling Mak, Celia, Xin Liang, Miao Zhang, Troncoso, Patricia, Song, Jian H., Song-Chang Lin, Xingzhi Song, Jingjing Liu, Jianhua Zhang, Logothetis, Christopher J., Melancon, Marites P., Panaretakis, Theocharis, Guocan Wang, and Sue-Hwa Lin

Subjects
*CASTRATION-resistant prostate cancer, *LYSYL oxidase, *BONE metastasis, *IMMUNE checkpoint proteins, *LYMPHATIC metastasis, *PROSTATE cancer patients
Abstract

Immune checkpoint therapy has limited efficacy for patients with bone-metastatic castration-resistant prostate cancer (bmCRPC). To improve immunotherapy for bmCRPC, we aimed to identify the mechanism of bmCRPC-induced changes in the immune microenvironment. Among bmCRPC patients, higher levels of a 32-gene M2-like macrophage signature in bone metastasis samples correlated with shorter overall survival. Immunohistochemistry showed that CD206-positive (CD206+) macrophages were enriched in bmCRPC bone biopsy specimens compared with primary tumors or lymph node metastases. In preclinical osteogenic prostate cancer (Pca) xenograft models, CD206+ macrophages were recruited to areas with tumor-induced bone. RNA sequencing (RNAseq) analysis showed higher expression of an M2-like gene signature, with activated canonical and noncanonical Wnt pathways, in tumor-associated macrophages isolated from osteogenic tumors (bone-TAMs) than in TAMs isolated from nonosteogenic tumors (ctrl-TAMs). Mechanistic studies showed that endothelial cells (ECs) that had undergone EC-to-osteoblast (EC-to-OSB) transition, the precursors of tumor-induced OSBs, produced paracrine factors, including Wnts, CXCL14, and lysyl oxidase, which induced M2 polarization and recruited M2-like TAMs to the bone-tumor microenvironment (bone-TME). Bone-TAMs suppressed CD8+ T cells' proliferation and cytolytic activity, and these effects were partially reversed by treating bone-TAMs with Wnt inhibitors. Genetic or pharmacological inhibition of Pca-induced EC-to-OSB transition reduced the levels of M2-like macrophages in osteogenic tumors. Our study demonstrates that Pca-induced EC-to-OSB transition drives immunosuppression in the bone-TME, suggesting that therapies that reduce Pca-induced bone formation may improve immunotherapeutic outcomes for bmCRPC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice.

Author

Lin, Song-Chang, Yu, Guoyu, Corn, Paul G., Damasco, Jossana, Lee, Yu-Chen, Song, Jian H., Navone, Nora M., Logothetis, Christopher J., Melancon, Marites P., Panaretakis, Theocharis, and Lin, Sue-Hwa

Subjects
OSTEOBLASTS, BONE density, RADIOTHERAPY, RESEARCH funding, T-test (Statistics), TRABECULECTOMY, COMPUTED tomography, PROSTATE tumors, DESCRIPTIVE statistics, MICE, ANIMAL experimentation, DATA analysis software
Abstract

Simple Summary: Radium 223 (Ra-223) is a radiopharmaceutical that targets tumor-induced osteoblasts (bone-forming cells). Ra-223 reduces bone pain and prolongs overall survival in men with bone-metastatic, castrate-resistant prostate cancer. However, increased fracture risk in skeletal sites with no bone metastasis has been observed in patients treated with Ra-223. The aim of this study was to examine the effects of Ra-223 on resident osteoblasts and normal bone structure in mouse models. Upon Ra-223 treatment, 70% of resident osteoblasts were reduced within 2 days, and the reduction lasted for at least 18 weeks. Ra-223 reduced the osteoblasts mainly localized in trabecular bone areas. Ra-223 also reduced bone mineral density and altered bone microstructure in the trabecular area of femurs. Furthermore, Ra-223 treatment also significantly reduced tumor-induced osteoblasts. These studies show that Ra-223 affects the structure of bones that are not involved in bone metastasis. Strategies that improve bone health may reduce fracture risk in patients receiving Ra-223. Radium 223 (Ra-223) is an α-emitting bone-homing radiopharmaceutical that targets tumor-induced osteoblasts and is used to reduce bone pain and prolong overall survival in men with bone-metastatic, castrate-resistant prostate cancer. However, increased fracture risk in skeletal sites with no bone metastasis has been observed in patients treated with Ra-223. Both luciferase- or green fluorescence protein (GFP)-labeled osteoblast reporter mice were used to monitor the effect of Ra-223 on resident osteoblasts and normal bone structure. Upon Ra-223 treatment, 70% of resident osteoblasts were reduced within 2 days, and the osteoblast reduction lasted for at least 18 weeks without detectable recovery, as measured by in vivo bioluminescent imaging. In GFP-labeled osteoblast reporter mice, Ra-223 mainly reduced osteoblasts localized in the trabecular bone areas; the osteoblasts in the growth plates were less affected. Micro-computed tomography analyses showed that Ra-223 significantly reduced bone mineral density and bone microstructure in the trabecular area of femurs but not in the cortical bone. Tumor-induced bone was generated by inoculating osteogenic TRAMP-BMP4 prostate cancer cells into the mouse femurs; Ra-223 treatment significantly reduced tumor-induced osteoblasts. Our study shows that Ra-223 affects bone structures that are not involved in bone metastasis. Strategies that improve bone health may reduce fracture risk in patients receiving Ra-223. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, additional, Shepherd, Peter D.A., additional, Dong, Jiabin, additional, Yang, Jun, additional, Song, Xiaofei, additional, Nandakumar, Subhiksha, additional, Kundra, Ritika, additional, Lee, Cindy, additional, Schultz, Nikolaus, additional, Zhang, Jianhua, additional, Araujo, John C., additional, Aparicio, Ana M., additional, Subudhi, Sumit K., additional, Corn, Paul G., additional, Pisters, Louis L., additional, Ward, John F., additional, Davis, John W., additional, Vazquez, Elba S., additional, Gueron, Geraldine, additional, Logothetis, Christopher J., additional, Futreal, Andrew, additional, Troncoso, Patricia, additional, Chen, Yu, additional, and Navone, Nora M., additional

Published
2024
Full Text
View/download PDF

10. MORPHOLOGICAL PROGRESSION IN RELAPSING PATIENTS WITH SMALL CELL BLADDER CANCER

Author

Moussa, Mohammad Jad, primary, Radtke, Arlene O. Siefker, additional, Shah, Amishi Y., additional, Gao, Jianjun, additional, Goswami, Sangeeta, additional, Logothetis, Christopher J., additional, Corn, Paul G., additional, Aparicio, Ana, additional, Tannir, Nizar M., additional, Kamat, Ashish M., additional, Navai, Neema, additional, Lee, Byron, additional, Dinney, Colin P.N., additional, Czerniak, Bogdan A., additional, Guo, Charles C., additional, Hansel, Donna E., additional, Campbell, Matthew T., additional, Alhalabi, Omar, additional, and Wilson, Nathaniel R., additional

Published
2024
Full Text
View/download PDF

11. FIGURE 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

12. FIGURE 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

13. Data from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

14. FIGURE 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

15. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., additional, Song, Jian H., additional, Hoang, Anh, additional, Shepherd, Peter D. A., additional, Ramachandran, Sumankalai, additional, Navone, Nora M., additional, Efstathiou, Eleni, additional, Titus, Mark, additional, Corn, Paul G., additional, Lin, Sue-Hwa, additional, Logothetis, Christopher J., additional, and Panaretakis, Theocharis, additional

Published
2023
Full Text
View/download PDF

16. FIGURE 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

17. FIGURE 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

19. FIGURE 6 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Author

Geng, Chuandong, primary, Zhang, Man-Chao, primary, Manyam, Ganiraju C., primary, Vykoukal, Jody V., primary, Fahrmann, Johannes F., primary, Peng, Shan, primary, Wu, Cheng, primary, Park, Sanghee, primary, Kondraganti, Shakuntala, primary, Wang, Daoqi, primary, Robinson, Brian D., primary, Loda, Massimo, primary, Barbieri, Christopher E., primary, Yap, Timothy A., primary, Corn, Paul G., primary, Hanash, Samir, primary, Broom, Bradley M., primary, Pilié, Patrick G., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Author

Geng, Chuandong, primary, Zhang, Man-Chao, primary, Manyam, Ganiraju C., primary, Vykoukal, Jody V., primary, Fahrmann, Johannes F., primary, Peng, Shan, primary, Wu, Cheng, primary, Park, Sanghee, primary, Kondraganti, Shakuntala, primary, Wang, Daoqi, primary, Robinson, Brian D., primary, Loda, Massimo, primary, Barbieri, Christopher E., primary, Yap, Timothy A., primary, Corn, Paul G., primary, Hanash, Samir, primary, Broom, Bradley M., primary, Pilié, Patrick G., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Author

Geng, Chuandong, primary, Zhang, Man-Chao, primary, Manyam, Ganiraju C., primary, Vykoukal, Jody V., primary, Fahrmann, Johannes F., primary, Peng, Shan, primary, Wu, Cheng, primary, Park, Sanghee, primary, Kondraganti, Shakuntala, primary, Wang, Daoqi, primary, Robinson, Brian D., primary, Loda, Massimo, primary, Barbieri, Christopher E., primary, Yap, Timothy A., primary, Corn, Paul G., primary, Hanash, Samir, primary, Broom, Bradley M., primary, Pilié, Patrick G., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

28. Data from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Author

Geng, Chuandong, primary, Zhang, Man-Chao, primary, Manyam, Ganiraju C., primary, Vykoukal, Jody V., primary, Fahrmann, Johannes F., primary, Peng, Shan, primary, Wu, Cheng, primary, Park, Sanghee, primary, Kondraganti, Shakuntala, primary, Wang, Daoqi, primary, Robinson, Brian D., primary, Loda, Massimo, primary, Barbieri, Christopher E., primary, Yap, Timothy A., primary, Corn, Paul G., primary, Hanash, Samir, primary, Broom, Bradley M., primary, Pilié, Patrick G., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

29. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Author

Geng, Chuandong, primary, Zhang, Man-Chao, additional, Manyam, Ganiraju C., additional, Vykoukal, Jody V., additional, Fahrmann, Johannes F., additional, Peng, Shan, additional, Wu, Cheng, additional, Park, Sanghee, additional, Kondraganti, Shakuntala, additional, Wang, Daoqi, additional, Robinson, Brian D., additional, Loda, Massimo, additional, Barbieri, Christopher E., additional, Yap, Timothy A., additional, Corn, Paul G., additional, Hanash, Samir, additional, Broom, Bradley M., additional, Pilié, Patrick G., additional, and Thompson, Timothy C., additional

Published
2023
Full Text
View/download PDF

30. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

Author

Tang, Chad, primary, Sherry, Alexander D., additional, Haymaker, Cara, additional, Bathala, Tharakeswara, additional, Liu, Suyu, additional, Fellman, Bryan, additional, Cohen, Lorenzo, additional, Aparicio, Ana, additional, Zurita, Amado J., additional, Reuben, Alexandre, additional, Marmonti, Enrica, additional, Chun, Stephen G., additional, Reddy, Jay P., additional, Ghia, Amol, additional, McGuire, Sean, additional, Efstathiou, Eleni, additional, Wang, Jennifer, additional, Wang, Jianbo, additional, Pilie, Patrick, additional, Kovitz, Craig, additional, Du, Weiliang, additional, Simiele, Samantha J., additional, Kumar, Rachit, additional, Borghero, Yerko, additional, Shi, Zheng, additional, Chapin, Brian, additional, Gomez, Daniel, additional, Wistuba, Ignacio, additional, and Corn, Paul G., additional

Published
2023
Full Text
View/download PDF

31. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer

Author

Fang, Andrew M., Chapin, Brian F., Shi, Charles W., Sun, Jia, Qayyum, Aliya, Kundra, Vikas, Corn, Paul G., Kuban, Deborah A., Ravizzini, Gregory C., Surasi, Devaki Shilpa S., Ma, Jingfei, and Bathala, Tharakeswara K.

Abstract

Background: Staging patients with high-risk prostate cancer (HRPCa) with conventional imaging of computed tomography (CT) and bone scintigraphy (BS) is suboptimal. Therefore, we aimed to compare the accuracy of whole-body magnetic resonance imaging (WBMRI) with conventional imaging to stage patients with HRPCa. Methods: We prospectively enrolled patients with newly diagnosed HRPCa (prostate‐specific antigen ≥20 ng/ml and/or Grade Group ≥4). Patients underwent BS, CT of the abdomen and pelvis, and WBMRI within 30 days of evaluation. The primary endpoint was the diagnostic performances of detecting metastatic disease to the lymph nodes and bone for WBMRI and conventional imaging. The reference standard was defined by histopathology or by all available clinical information at 6 months of follow-up. To compare diagnostic tests, Exact McNemar’s test and area under the curve (AUC) of the receiver operating characteristics curves were utilized. Results: Among 92 patients enrolled, 15 (16.3%) and 8 (8.7%) patients were found to have lymphatic and bone metastases, respectively. The sensitivity, specificity, and accuracy of WBMRI in detecting lymphatic metastases were 0.60 (95% confidence interval 0.32–0.84), 0.84 (0.74–0.92), and 0.80 (0.71–0.88), respectively, while CT were 0.20 (0.04–0.48), 0.92 (0.84–0.97), and 0.80 (0.71–0.88). The sensitivity, specificity, and accuracy of WBMRI to detect bone metastases were 0.25 (0.03–0.65), 0.94 (0.87–0.98), and 0.88 (0.80–0.94), respectively, while CT and BS were 0.12 (0–0.53), 0.94 (0.87–0.98), and 0.87 (0.78–0.93). For evaluating lymphatic metastases, WBMRI demonstrated a higher sensitivity (p= 0.031) and discrimination compared to CT (0.72 versus 0.56, p= 0.019). Conclusions: For staging patients with HRPCa, WBMRI outperforms CT in the detection of lymphatic metastases and performs as well as CT and BS in the detection of bone metastases. Further studies are needed to assess the cost effectiveness of WBMRI and the utility of combined PSMA PET and WBMRI.

Published
2024
Full Text
View/download PDF

32. Body composition as a determinant of the therapeutic index with androgen signaling inhibition

Author

Hahn, Andrew W., Tidwell, Rebecca S., Pilie, Patrick G., Yu, Yao, Liu, Jingjing, Surasi, Devaki Shilpa, Titus, Mark, Zhang, Jianhua, Venkatesh, Neha, Panaretakis, Theocharis, Gregg, Justin R., Zurita, Amado J., Siddiqui, Bilal A., Corn, Paul G., Subudhi, Sumit K., Msaouel, Pavlos, Koutroumpakis, Efstratios, Huff, Chad D., Aparicio, Ana, McQuade, Jennifer L., Frigo, Daniel E., and Logothetis, Christopher J.

Abstract

Background: Androgen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI. We hypothesized that host adiposity and androgen synthesis are linked to the efficacy and toxicity of ASI for men with metastatic castration-resistant prostate cancer (mCRPC). Methods: A post-hoc analysis was done of NCT02703623 where men with mCRPC (n= 186) were treated for 8 weeks with abiraterone acetate, prednisone, and apalutamide (AAPA), and a satisfactory response was defined as a PSA decline >50%. Body composition was measured on baseline CT scans. Germline DNA WES was performed with a focus on variants in steroidogenic genes. Adipokine levels were measured in pre-treatment plasma. Results: Germline polymorphisms in 3 genes involved in androgen synthesis (AKR1C3rs12529, CYP17A1rs6162, SRD5A2rs523349) were associated with differences in body composition at baseline on ADT alone (prior to receipt of AAPA). Elevated subcutaneous adipose tissue index (SATi, p= 0.02), visceral adipose tissue index (VATi, p= 0.03), and BMI (p= 0.04) were associated with satisfactory response to AAPA. Leptin had positive correlation with VATi (r= 0.47) and SATi (r= 0.48). Conclusion: Inherited polymorphisms in androgen synthesis correlated with differences in body composition after exposure to ADT and warrant further investigation as candidate markers for body composition toxicity. Elevated subcutaneous and visceral adiposity were associated with improved response to ASI.

Published
2024
Full Text
View/download PDF

33. Supplementary Figure from Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition

Author

Yu, Guoyu, primary, Corn, Paul G., primary, Shen, Pengfei, primary, Song, Jian H., primary, Lee, Yu-Chen, primary, Lin, Song-Chang, primary, Pan, Jing, primary, Agarwal, Sandeep K., primary, Panaretakis, Theocharis, primary, Pacifici, Maurizio, primary, Logothetis, Christopher J., primary, Yu-Lee, Li-Yuan, primary, and Lin, Sue-Hwa, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition

Author

Yu, Guoyu, primary, Corn, Paul G., primary, Shen, Pengfei, primary, Song, Jian H., primary, Lee, Yu-Chen, primary, Lin, Song-Chang, primary, Pan, Jing, primary, Agarwal, Sandeep K., primary, Panaretakis, Theocharis, primary, Pacifici, Maurizio, primary, Logothetis, Christopher J., primary, Yu-Lee, Li-Yuan, primary, and Lin, Sue-Hwa, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table from Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition

Author

Yu, Guoyu, primary, Corn, Paul G., primary, Shen, Pengfei, primary, Song, Jian H., primary, Lee, Yu-Chen, primary, Lin, Song-Chang, primary, Pan, Jing, primary, Agarwal, Sandeep K., primary, Panaretakis, Theocharis, primary, Pacifici, Maurizio, primary, Logothetis, Christopher J., primary, Yu-Lee, Li-Yuan, primary, and Lin, Sue-Hwa, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

Author

Corn, Paul G., primary, Zhang, Miao, primary, Nogueras-Gonzalez, Graciela M., primary, Xiao, Lianchun, primary, Zurita, Amado J., primary, Subudhi, Sumit K., primary, Tu, Shi-Ming, primary, Aparicio, Ana M., primary, Coarfa, Cristian, primary, Rajapakshe, Kimal, primary, Huang, Shixia, primary, Navone, Nora M., primary, Lin, Sue-Hwa, primary, Wang, Guocan, primary, Ramachandran, Sumankalai, primary, Titus, Mark A., primary, Panaretakis, Theocharis, primary, Gallick, Gary E., primary, Efstathiou, Eleni, primary, Troncoso, Patricia, primary, and Logothetis, Christopher, primary

Published
2023
Full Text
View/download PDF

37. Table S4 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

Author

Zhang, Wei, primary, Liu, Bo, primary, Wu, Wenhui, primary, Li, Likun, primary, Broom, Bradley M., primary, Basourakos, Spyridon P., primary, Korentzelos, Dimitrios, primary, Luan, Yang, primary, Wang, Jianxiang, primary, Yang, Guang, primary, Park, Sanghee, primary, Azad, Abul Kalam, primary, Cao, Xuhong, primary, Kim, Jeri, primary, Corn, Paul G., primary, Logothetis, Christopher J., primary, Aparicio, Ana M., primary, Chinnaiyan, Arul M., primary, Navone, Nora, primary, Troncoso, Patricia, primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

38. Figure S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

Author

Zhang, Wei, primary, Liu, Bo, primary, Wu, Wenhui, primary, Li, Likun, primary, Broom, Bradley M., primary, Basourakos, Spyridon P., primary, Korentzelos, Dimitrios, primary, Luan, Yang, primary, Wang, Jianxiang, primary, Yang, Guang, primary, Park, Sanghee, primary, Azad, Abul Kalam, primary, Cao, Xuhong, primary, Kim, Jeri, primary, Corn, Paul G., primary, Logothetis, Christopher J., primary, Aparicio, Ana M., primary, Chinnaiyan, Arul M., primary, Navone, Nora, primary, Troncoso, Patricia, primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Author

Aparicio, Ana M., primary, Harzstark, Andrea L., primary, Corn, Paul G., primary, Wen, Sijin, primary, Araujo, John C., primary, Tu, Shi-Ming, primary, Pagliaro, Lance C., primary, Kim, Jeri, primary, Millikan, Randall E., primary, Ryan, Charles, primary, Tannir, Nizar M., primary, Zurita, Amado J., primary, Mathew, Paul, primary, Arap, Wadih, primary, Troncoso, Patricia, primary, Thall, Peter F., primary, and Logothetis, Christopher J., primary

Published
2023
Full Text
View/download PDF

40. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Author

Siddiqui, Bilal A, primary, Chapin, Brian F, additional, Jindal, Sonali, additional, Duan, Fei, additional, Basu, Sreyashi, additional, Yadav, Shalini S, additional, Gu, Ai-Di, additional, Espejo, Alexsandra B, additional, Kinder, Michelle, additional, Pettaway, Curtis A, additional, Ward, John F, additional, Tidwell, Rebecca S S, additional, Troncoso, Patricia, additional, Corn, Paul G, additional, Logothetis, Christopher J, additional, Knoblauch, Roland, additional, Hutnick, Natalie, additional, Gottardis, Marco, additional, Drake, Charles G, additional, Sharma, Padmanee, additional, and Subudhi, Sumit K, additional

Published
2023
Full Text
View/download PDF

41. Neoplasms of the Prostate

Author

Aparicio, Ana, primary, Pilie, Patrick, additional, Surasi, Devaki S., additional, Choi, Seungtaek, additional, Chapin, Brian F., additional, Logothetis, Christopher J., additional, and Corn, Paul G., additional

Published
2022
Full Text
View/download PDF

42. Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Author

Fecteau, Ryan E., Koontz, Bridget F., Hoffman, Karen E., Halabi, Susan, Howard, Lauren E., Anand, Monika, George, Daniel J., Zhang, Tian, Berry, William R., Lee, W. Robert, Harrison, Michael R., Corn, Paul G., and Armstrong, Andrew J.

Abstract

Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

Published
2024
Full Text
View/download PDF

43. Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

Author

Anselmino, Nicolas, primary, Labanca, Estefania, additional, Song, Xiaofei, additional, Yang, Jun, additional, Shepherd, Peter DA, additional, Dong, Jiabin, additional, Kundra, Ritika, additional, Schultz, Nikolas, additional, Zhang, Jianhua, additional, Araujo, John C., additional, Aparicio, Ana M, additional, Subudhi, Sumit K., additional, Corn, Paul G., additional, Pisters, Louis L., additional, Ward, John F., additional, Davis, John W., additional, Gueron, Geraldine, additional, Vazquez, Elba S., additional, Logothetis, Christopher J, additional, Futreal, Andrew, additional, Troncoso, Patricia, additional, Chen, Yu, additional, and Navone, Nora M, additional

Published
2022
Full Text
View/download PDF

44. Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition

Author

Yu, Guoyu, primary, Corn, Paul G., additional, Shen, Pengfei, additional, Song, Jian H., additional, Lee, Yu-Chen, additional, Lin, Song-Chang, additional, Pan, Jing, additional, Agarwal, Sandeep K., additional, Panaretakis, Theocharis, additional, Pacifici, Maurizio, additional, Logothetis, Christopher J., additional, Yu-Lee, Li-Yuan, additional, and Lin, Sue-Hwa, additional

Published
2022
Full Text
View/download PDF

45. Activation of retinoic acid receptor reduces metastatic prostate cancer bone lesions through blocking endothelial-to-osteoblast transition

Author

Yu, Guoyu, primary, Corn, Paul G., additional, Shen, Pengfei, additional, Song, Jian H., additional, Lee, Yu-Chen, additional, Lin, Song-Chang, additional, Pan, Jing, additional, Agarwal, Sandeep K., additional, Panaretakis, Theocharis, additional, Pacifici, Maurizio, additional, Logothetis, Christopher J., additional, Yu-Lee, Li-Yuan, additional, and Lin, Sue-Hwa, additional

Published
2021
Full Text
View/download PDF

47. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma

Author

Alhalabi, Omar, primary, Campbell, Matthew T., additional, Xiao, Lianchun, additional, Adriazola, Ana C., additional, Wilson, Nathaniel R., additional, Siefker‐Radtke, Arlene O., additional, Corn, Paul G., additional, Zurita, Amado, additional, Jonasch, Eric, additional, Gao, Jianjun, additional, Adibi, Mehrad, additional, Kamat, Ashish M., additional, Navai, Neema, additional, Pisters, Louis L., additional, Dinney, Colin, additional, Matin, Surena F., additional, and Shah, Amishi Y., additional

Published
2021
Full Text
View/download PDF

48. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Author

Subudhi, Sumit K, primary, Siddiqui, Bilal A, additional, Aparicio, Ana M, additional, Yadav, Shalini S, additional, Basu, Sreyashi, additional, Chen, Hong, additional, Jindal, Sonali, additional, Tidwell, Rebecca S S, additional, Varma, Ashwin, additional, Logothetis, Christopher J, additional, Allison, James P, additional, Corn, Paul G, additional, and Sharma, Padmanee, additional

Published
2021
Full Text
View/download PDF

50. Body composition in recurrent prostate cancer and the role of steroidogenic genotype.

Author

Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, and Hahn AW

Abstract

Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biologic and clinical determinants of body composition toxicity are unknown. Herein, we test the hypothesis that inherited polymorphisms in steroidogenic genes are associated with differential change in body composition after HT. Men with biochemically recurrent prostate cancer (BCR) who received 8 months of LHRH analog (LHRHa) +/- abiraterone acetate (AAP) were eligible if they had: 1) CT imaging of L3 prior to and after treatment, and 2) nucleated cells collected. Cardiometabolic co-morbidities were retrospectively extracted. Body composition was measured using an AI-based segmentation tool. Germline DNA whole exome or genome sequencing was performed. In 162 men treated with 8 months of HT, median skeletal muscle mass (SMMi) loss was 6.6% and subcutaneous adipose gain was 12.3%. Men with type 2 diabetes had higher loss of SMMi after treatment (-11.1% vs. -6.3%, p = 0.003). For the 150 men with germline NGS, SRD5A2 rs523349 genotype was associated with differential loss in skeletal muscle density after HT, (-1.3% vs. -7.1%, p=0.04). In addition, HSD3B1 rs104703 genotype was associated with decreased baseline visceral adipose tissue (63.0 cm2/m2 vs. 77.9, p=0.05). In men with BCR, HT induced notable loss of skeletal muscle and increased subcutaneous adipose tissue. An inherited polymorphism in SRD5A2 and T2DM were associated with differential skeletal muscle toxicity. These findings suggest that inherited polymorphisms may contribute to the body composition toxicity observed with HT.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results